Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Corvus Pharmaceuticals (CRVS) Shares Outstanding (2022 - 2025)

Corvus Pharmaceuticals has reported Shares Outstanding over the past 4 years, most recently at $74.7 million for Q3 2025.

  • Quarterly results put Shares Outstanding at $74.7 million for Q3 2025, up 19.34% from a year ago — trailing twelve months through Sep 2025 was $74.7 million (up 19.34% YoY), and the annual figure for FY2024 was $67.9 million, up 38.46%.
  • Shares Outstanding for Q3 2025 was $74.7 million at Corvus Pharmaceuticals, roughly flat from $74.5 million in the prior quarter.
  • Over the last five years, Shares Outstanding for CRVS hit a ceiling of $74.7 million in Q3 2025 and a floor of $46.6 million in Q1 2022.
  • Median Shares Outstanding over the past 4 years was $49.0 million (2023), compared with a mean of $55.9 million.
  • Biggest five-year swings in Shares Outstanding: rose 0.03% in 2023 and later skyrocketed 39.01% in 2025.
  • Corvus Pharmaceuticals' Shares Outstanding stood at $46.6 million in 2022, then grew by 5.34% to $49.0 million in 2023, then surged by 38.46% to $67.9 million in 2024, then grew by 9.99% to $74.7 million in 2025.
  • The last three reported values for Shares Outstanding were $74.7 million (Q3 2025), $74.5 million (Q2 2025), and $68.2 million (Q1 2025) per Business Quant data.